<DOC>
	<DOCNO>NCT00380614</DOCNO>
	<brief_summary>Since proportion patient Acute Viral Hepatitis-B develop severe hepatitis fulminant hepatic failure , logical believe rapid reduction HBV DNA level use antiviral agent could result less intense host response hepatitis B virus . However , experience lamivudine treatment immunocompetent patient AVH-B limited.The aim present study evaluate efficacy , utility safety lamivudine treat immunocompetent patient AVH-B .</brief_summary>
	<brief_title>A Randomized Controlled Trial Lamivudine Acute Hepatitis B</brief_title>
	<detailed_description>The diagnosis acute hepatitis B base recent onset acute illness include prodromal symptom , jaundice typical symptom . The laboratory investigation support diagnosis acute hepatitis include presence &gt; 2.5 time upper limit serum alanine aminotransferase ( ALT ) serum bilirubin , positive IgM anti-HBc test . Ultrasound , esophagogastroduodenoscopy do look evidence chronic liver disease . All patient normal alpha-fetoprotein level . Co-infection hepatitis A , C , D , E human immunodeficiency virus ( HIV ) infection look appropriate serologic test conduct within 7 day presentation . Patients co-infection , history hepatotoxic drug intake alcohol use &gt; 20g/day , evidence chronic liver disease past , presentation follow-up exclude . Patients also exclude serum bilirubin &lt; 5 mg/dl presentation . Patients classify severe AVH-B fulfil two follow criterion : ( 1 ) hepatic encephalopathy ; ( 2 ) serum bilirubin ≥10.0 mg/dl ; ( 3 ) international normalize ratio ( INR ) ≥1.6 . The patient randomize 2 group : Group 1 : Treatment lamivudine 100 mg daily 3 month , Group 2 : Placebo . Randomization do use random number table . The initial study randomization plan enroll 120 patient continue study till three year , whichever early . Individual rather block randomization do The investigator well patient blind randomisation . The patient placebo group receive placebo pill . All patient monitor treatment clinical evidence grade hepatic encephalopathy , impaired coagulation ( abnormal international normalize ratio , IINR ) , AST/ALT , serum albumin bilirubin level every week first month monthly . HBV serology , include serum HBsAg , HBeAg , anti-HBe checked baseline every 3 month . Anti-HBs titre check 6 12 month . Quantitative HBV DNA assay perform day 0 , day 4 , week 1 , week 2 , week 3 , week 4 , every month next 2 month every 3 month 12 month . All patient follow least 12 month onset AVH-B . Development protective anti-HBs ( &gt; 10 IU/L ) specifically look . Exacerbation chronic hepatitis B exclude investigate thoroughly evidence chronic liver disease Ultrasound , Upper GI endoscopy , low albumin presentation . Ultrasound repeat 6 12 month , suspicion Upper GI endoscopy also repeat . LFTS do every hospital visit . HBsAg , HBeAg , IgM anti-HBc , anti-HBs , anti-HBe test commercially available enzyme-linked immunoassay . Serum quantitative HBV DNA assay perform use ultra sensitive Hybrid capture assay [ Digene Labs , USA ] low limit detection 4,700 copies/ml . An arbitrary value 4,700 copies/ml assign value &lt; 4,700 copies/ml analysis purpose . In patient HBV DNA do in-house qualitative PCR test indicate negativity positivity viral DNA . The low limit detection 600 copies/ml .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Diagnosis acute hepatitis B Bilirubin &gt; 5 mg/dl presentation . Patients coinfection , history hepatotoxic drug intake alcohol use &gt; 20g/day , evidence chronic liver disease past , presentation followup</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Acute Hepatitis B , Lamivudine</keyword>
</DOC>